Mar 15, 2023 / 02:45PM GMT
Carter Lewis Gould - Barclays Bank PLC, Research Division - Senior Analyst
Good morning, and welcome to Day 2 of the Barclays Global Healthcare Conference. My name is Carter Gould, senior biopharma analyst here at Barclays.
I am pleased to welcome Neurocrine Biosciences, just recently celebrating your 30th Anniversary. Joining us on stage, Kevin Gorman, CEO; and CFO, Matt Abernethy.
Kevin is going to make some opening comments.
Kevin C. Gorman - Neurocrine Biosciences, Inc. - CEO & Director
I will make -- I'll keep them brief. And I want to thank Barclays, I want to thank you, Carter, for the invitation here. We always love coming to this conference in Miami. I would also say that we are going to be making forward-looking statements. So I would -- you to our more recent SEC filings.
So as Carter said, Neurocrine just recently celebrated its 30th Anniversary. We are a (inaudible) world neuroscience company. What does neuroscience mean to us? That means neurology, neuropsychiatry and neuroendocrinology and hopefully, someday,
Neurocrine Biosciences Inc at Barclays Global Healthcare Conference Transcript
Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot